iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy.
| Revenue (TTM) | 523,030 |
| Gross Profit (TTM) | 327,350 |
| EBITDA | $-5.17M |
| Operating Margin | -682.00% |
| Return on Equity | -71.30% |
| Return on Assets | -41.00% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.36 |
| Price-to-Book | 0.67 |
| Price-to-Sales (TTM) | 12.24 |
| EV/Revenue | 2.503 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 91.60% |
| Shares Outstanding | $9.38M |
| Float | $15.64M |
| % Insiders | 1.82% |
| % Institutions | 0.10% |
New cloud-based platform is being developed to integrate artificial intelligence, automated quality control and healthcare data connectivity to support next-generation precision medicine workflows.
BEIJING, China, April 23, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (the “Company” or “ITOC”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced that on April 21, 2026, it received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that Nasdaq approved the Company's request for an extension of additional 180-calendar day, or until October 19, 2026 (the “Extension”) to regain compliance with the minimum closing bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”).The Extension follows the expiration the initial 180-calendar day compliance period on April 20, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ITOC and any ticker you trade — then tracks every position and per-strategy win rate.
